May 16, 2025

FDA Approves PD-1–Targeted Monoclonal Antibody for SCAC

The FDA has approved Zynyz (retifanlimab-dlwr) as the first programmed death receptor-1 inhibitor for first-line treatment of advanced squamous cell carcinoma of the anal canal.

Conexiant

May 06, 2025

Shorter Prostate Radiotherapy Proves Long-Term Match

Two-week radiation treatment for localized prostate cancer delivers equivalent 10-year outcomes to standard 8-week course in a clinical trial.

Conexiant

May 06, 2025

Two- vs 8-Week Course of Radiotherapy for Prostate Cancer: 10-Year Follow-up

The phase III HYPO-RT-PC reported 10-year follow-up exploring shorter course radiotherapy for localized prostate cancer. The findings were presented at ESTRO 2025      

The ASCO Post

May 05, 2025

FDA Monthly Round-up: Key April Updates

April’s FDA approvals feature first-in-class therapies, targeted biologics, expanded indications, and innovative delivery systems across allergy, endocrinology, rheumatology, oncology, infectious diseases, and more.

Conexiant

April 29, 2025

Machine Learning Boosts Bone Tumor Diagnosis: New System Shows High Accuracy

Machine learning may help reshape bone tumor diagnostics, offering radiologists a new tool for classifying bone lesions and standardizing risk communication.

Conexiant

April 24, 2025

Vitamin D Multifaceted CRC Immunomodulator Revealed

"Vitamin D enhances immune organ functions such as the spleen and lymph nodes, and boosts T-cell activity, which is essential in defending the body against tumors."

Conexiant

April 24, 2025

Proton Therapy and Intensity-Modulated Radiation Therapy for Localized Prostate Cancer

Proton beam therapy and intensity-modulated radiation therapy (IMRT) were found to offer equivalent quality-of-life outcomes for patients with localized prostate cancer, according to data from the PAR...

The ASCO Post

April 23, 2025

Sense of Belonging 'Critical' for Workplace Retention

Individuals who reported a neutral level of satisfaction with their sense of belonging were approximately 3 times more likely to express an intent to leave, while those who were dissatisfied were 7 times more likely to do so, compared to individuals who were satisfied with their sense of belonging.

Conexiant

April 01, 2025

FDA Approves Freeze-Dried Jynneos Vaccine

Bavarian Nordic’s freeze-dried Jynneos vaccine offers logistical advantages over the liquid-frozen version, supporting long-term U.S. stockpiling and public health preparedness.

Conexiant